Chaewon Song, MD
Geriatric Medicine · Garden Grove, CANPI 1972589687
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 1,037 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 52 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. Among geriatric medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,037 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$2K
- Pfizer$2K
- Lilly USA, LLC$1K
- Amgen$1K
- Novartis$1K
- plus $12K from 46 others
What the payments were for
- Food & beverage$20,73999%
- Education$2971%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,036 in reported general payments places this provider in the 95th percentile of 494 geriatric medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 927 | $822,233 |
| ZenpepLipase/Protease/Amylase | 318 | $398,637 |
| JanumetSitagliptin Phos/Metformin Hcl | 501 | $356,235 |
| VascepaIcosapent Ethyl | 878 | $350,745 |
| EliquisApixaban | 436 | $230,299 |
| JardianceEmpagliflozin | 193 | $186,538 |
| TradjentaLinagliptin | 311 | $184,254 |
| JanuviaSitagliptin Phosphate | 286 | $171,253 |
| ProliaDenosumab | 92 | $153,483 |
| LinzessLinaclotide | 222 | $132,815 |
| FarxigaDapagliflozin Propanediol | 167 | $124,659 |
| Lidocaine | 480 | $82,079 |
| TrulicityDulaglutide | 77 | $79,429 |
| OzempicSemaglutide | 76 | $79,075 |
| MyrbetriqMirabegron | 115 | $63,534 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Restasis | $2,453 | $988,3301,209 claims |
| MerckJanumet, Januvia, Janumet Xr | $62 | $566,060839 claims |
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto | $780 | $399,433548 claims |
| Aimmune Therapeutics, Inc.Zenpep | $755 | $398,637318 claims |
| PfizerEliquis | $1,590 | $230,299436 claims |
| AmgenProlia | $1,043 | $153,48392 claims |
| AstraZenecaFarxiga, Brilinta | $839 | $135,690193 claims |
| Lilly USA, LLCTrulicity | $1,310 | $79,42977 claims |
| Novo NordiskOzempic | $1,899 | $79,07576 claims |
| Astellas Pharma US IncMyrbetriq | $825 | $63,534115 claims |
| Johnson & JohnsonXarelto | $708 | $48,94781 claims |
| GSKAnoro Ellipta, Breo Ellipta | $512 | $31,27967 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 494 geriatric medicine providers in California.
Other geriatric medicine in Garden Grove
- Robert FeldmanLaguna Hills$1.2M
- Oscar ChienSan Gabriel$208K
- Anders NybergSan Diego$160K
- Paul AisenSan Diego$70K
- Wayne ChenLos Angeles$40K
- Vincent HoLancaster$32K
- Kathryn SewellSan Francisco$26K
- Stephen HenryPasadena$25K
- Douglas ZhangSan Leandro$20K
- Hermenegildo AngelesDaly City$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.